Opinion|Videos|March 15, 2025
GPP Pathogenesis and Treatment Goals
Panelists discuss recent advances in understanding the pathogenesis of generalized pustular psoriasis (GPP) and how these insights have influenced the approach to and management of the disease. They also outline their immediate and long-term treatment goals for patients with GPP, focusing on symptom control and long-term disease management.
Advertisement
Video content above is prompted by the following:
Episodes in this series
- What have we learned in recent years about the pathogenesis of GPP, and how has this affected the way we think about and manage the disease?
- What are your immediate and long-term treatment goals for patients with GPP?
Advertisement
Related to this article
Catch up on HCPLive’s second-half Fall Clinical 2026 coverage, from HS underdiagnosis in men and long-term acne data to advanced cutaneous SCC care.
In mice, liraglutide reduced steatosis through PPARα without needing iNKT cells, pointing to a possible GLP-1 RA plus PPARα combination.
In pooled, propensity-matched data, SC infliximab achieved week 54 endoscopic response in 65.7% of patients with ileal Crohn’s disease vs 27.1% with IV.
In ADtouch, lebrikizumab improved clearance, itch, and pain in hand and foot atopic dermatitis. Shawn Kwatra, MD, discusses what the data mean.
Phase 3 SHINE-2 data show 41.3% of children and adolescents with UC reached clinical remission after 12 weeks of mirikizumab induction.
A roundup of highlights from EADV Congress 2026 in Vienna, spanning dupilumab real-world data, pipeline biologics, and a first-in-class oral agent.
Among 155 patients aged 0 to 24 months, 96.1% of episodes were food-triggered and 90.4% of epinephrine recipients received only 1 dose.
In a LIBERTY post hoc analysis, most patients restarting infliximab as SC 240 mg after a drug holiday had prior ADAs, yet outcomes were similar.
Advertisement
Advertisement
Trending on HCPLive
1
Oral Icotrokinra Sustains UC Response Through 76 Weeks in ANTHEM-UC LTE
2
Guselkumab Sustains Histologic Healing in Ulcerative Colitis Over 3 Years
3
CHEST 2026 Preview: Late-Breakers to Watch Out For
4
Rezpegaldesleukin Hair Regrowth Climbs Through 1 Year in AA: David Rosmarin, MD
5